SEC Comment Letter 0000000000-24-006054 to Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc.
Date: May 24, 2024 · CIK: 0002012593 · Accession: 0000000000-24-006054
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279486
Letter
United States securities and exchange commission logo May 24, 2024 Troy Ignelzi Chief Financial Officer Rapport Therapeutics, Inc. 1325 Boylston Street, Suite 401 Boston, MA 02215 Re:Rapport Therapeutics, Inc. Registration Statement on Form S-1 Filed May 17, 2024 File No. 333-279486 Dear Troy Ignelzi: We have reviewed your registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-1 filed May 17, 2024 Risks Associated With Our Business, page 7 1.We note your revised disclosure at the bottom of page 29 in response to prior comment 1. Please add a new Summary risk factor bullet point that highlights this specific risk. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
FirstName LastNameTroy Ignelzi Comapany NameRapport Therapeutics, Inc. May 24, 2024 Page 2 FirstName LastName Troy Ignelzi Rapport Therapeutics, Inc. May 24, 2024 Page 2 Please contact Jenn Do at 202-551-3743 or Daniel Gordon at 202-551-3486 if you have questions regarding comments on the financial statements and related matters. Please contact Tamika Sheppard at 202-551-8346 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Justin Platt
Show Raw Text
United States securities and exchange commission logo
May 24, 2024
Troy Ignelzi
Chief Financial Officer
Rapport Therapeutics, Inc.
1325 Boylston Street, Suite 401
Boston, MA 02215
Re:Rapport Therapeutics, Inc.
Registration Statement on Form S-1
Filed May 17, 2024
File No. 333-279486
Dear Troy Ignelzi:
We have reviewed your registration statement and have the following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1 filed May 17, 2024
Risks Associated With Our Business, page 7
1.We note your revised disclosure at the bottom of page 29 in response to prior comment 1.
Please add a new Summary risk factor bullet point that highlights this specific risk.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
FirstName LastNameTroy Ignelzi
Comapany NameRapport Therapeutics, Inc.
May 24, 2024 Page 2
FirstName LastName
Troy Ignelzi
Rapport Therapeutics, Inc.
May 24, 2024
Page 2
Please contact Jenn Do at 202-551-3743 or Daniel Gordon at 202-551-3486 if you have
questions regarding comments on the financial statements and related matters. Please contact
Tamika Sheppard at 202-551-8346 or Joe McCann at 202-551-6262 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Justin Platt